Discover 1,825 paid clinical trials in Greensboro, North Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,825
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
for
Acute Myeloid Leukemia
Location: Winston-Salem NC, Durham NC, Charlotte NC,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06672146
Phase 2, Recruiting
Evaluation of Flexible Conductive Hearing Aids
for
Conductive Hearing Loss
Location: Winston-Salem NC
Sponsor: Wake Forest University Health Sciences
Sex: All
Age: 0 - 70+
Code: NCT07222202
Recruiting
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
for
Hypertension, Left Ventricular Hypertrophy,
Location: Winston-Salem NC
Sponsor: Wake Forest University Health Sciences
Sex: All
Age: 7 - 18
Code: NCT04752293
Recruiting
Human Immunodeficiency Virus (HIV) Food Insecurities
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
for
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Location: Winston-Salem NC, Chapel Hill NC, Durham NC,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 1 - 30
Code: NCT04546399
Phase 2, Recruiting
Feasibility of an ADAPTive Intervention to Improve Food Security and Maternal-Child Health
for
Food Insecurity, Pregnancy
Location: Winston-Salem NC
Sponsor: Wake Forest University Health Sciences
Sex: Female
Age: 18+
Code: NCT06942598
Recruiting
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
for
B Acute Lymphoblastic Leukemia
Location: Winston-Salem NC, Chapel Hill NC, Durham NC, Roanoke VA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 1 - 46
Code: NCT06124157
Phase 2, Recruiting
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis